Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tesaro, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Colorado, Denver
University of Pittsburgh
AstraZeneca
Mayo Clinic
AstraZeneca
University of Kansas Medical Center
City of Hope Medical Center
Tesaro, Inc.
National Cancer Institute (NCI)
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
AstraZeneca
National Cancer Institute (NCI)
Medtronic - MITG
M.D. Anderson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
AstraZeneca
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
pharmaand GmbH
Medical College of Wisconsin
Dana-Farber Cancer Institute